Jerini Appoints Andrew D. Curtis as Vice President U.S. Marketing for Jerini U.S., Inc.
BERLIN, May 2, 2006 (PRIMEZONE) -- Jerini AG (Xetra: 678747 - news) (FSE:JI4) announced the appointment of Andrew D. Curtis as Vice President
Advertisement
U.S. Marketing, effective May 1, 2006. Curtis will be heading Jerini's recently established subsidiary, Jerini U.S., Inc., headquartered in the New York metropolitan area. "We are extremely pleased to welcome Andrew to Jerini's team," said Jens Schneider-Mergener, CEO of Jerini. "His extensive marketing and business development experience are vital for this key position, allowing Jerini to strengthen and expand our U.S. presence. Jerini U.S. will also work closely with our U.S. partner, Kos Pharmaceuticals, Inc., to coordinate the planned North American market launch of our lead product, Icatibant, for hereditary angioedema in 2007."
Andrew Curtis brings more than ten years of pharmaceutical experience, joining Jerini after three years at Pfizer, where he most recently served as U.S. Marketing Director for ARICEPT. Curtis began his pharmaceutical career at Aventis and has held marketing and sales positions at Merck, Genzyme, and J&J. In his previous positions, he successfully managed product filings and launches, and gained expertise in the areas of orphan drugs and rare genetic diseases, metabolic bone disease, burn treatment, and vaccine therapy... |
